Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

Seoul National University Hospital20 enrolled

Overview

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Constipated Irritable Bowel Syndrome Chronic Constipation Healthy

Interventions

MosaprideDRUG

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria Exclusion Criteria: * Intolerable or hypersensitive to mosapride * Known Parkinson's ds * Cardio- or cerebrovascular disease within 3 months * Malignancy requiring surgery or chemotherapy or radiation within 5 years * History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation * Refractory diabetes mellitus/hypertension/thyroid diseases * Symptomatic heart failure, renal failure, arrhythmia

Outcomes

Primary Outcomes

colonic transit time

the change of colonic transit time after mosapride 30mg/day administration : whole colonic transit time, rt. colon / lt. colon / rectosigmoid colonic transit time

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.